# Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-alone-or-in-combination-with-cisplatin-plus-gemcitabine-in-japanese/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Makoto Ueno,Masafumi Ikeda,Chigusa Morizane,Satoshi Kobayashi,Izumi Ohno,Shunsuke Kondo,Naohiro Okano,Keisuke Kimura,Suguru Asada,Yoshinobu Namba,Takuji Okusaka,Junji Furuse |
| Citations | 334 |
| DOI | 10.1016/s2468-1253(19)30086-x |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2946053006 |
| PMID | 31109808 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Izumi Ohno](https://scholariq.org/researchers/izumi-ohno/)

## Paper journal

- [˜The œLancet. Gastroenterology & hepatology](https://scholariq.org/journals/the-lancet-gastroenterology-and-hepatology/)

## Paper primary topic

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

## Paper topics

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.